The Latest Breaking News from Novo Nordisk

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

Melissa Lee reports for ‘Big Shot: The Ozempic Revolution,’ debuting Feb. 29

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?